Talquetamab

Summary

Talquetamab (CHEMBL4594503) is an approved antibody (ATC L01FX29) targeting GPRC5D; indicated across 3 conditions including plasma cell myeloma and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L01FX29
• Targets: 1 (GPRC5D)
• Indications: 3 conditions
• Clinical trials: 35

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594503
Name	Talquetamab
Type	Antibody
Max phase	4
ATC	L01FX29

Also known as: JNJ-63483043, JNJ-64407564, Talquetamab, Talquetamab-tgvs, Talvey, TALQUETAMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GPRC5D	GPRC5D	Binding		0%	Q9NZD1

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): GPRC5D.

Dominant GO biological processes

GO term	Targets
signal transduction	1
G protein-coupled receptor signaling pathway	1

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plasma cell myeloma	4	MONDO:0009693	EFO:0001378
neoplasm	4	MONDO:0005070	EFO:0000616
hematologic disorder	2	MONDO:0005570	MONDO:0005570

Clinical trials

Total trials: 35.

Phase distribution

Phase	Trials
PHASE2	16
PHASE1	8
Not specified	5
PHASE3	4
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05455320	PHASE3	ACTIVE_NOT_RECRUITING	A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05552222	PHASE3	RECRUITING	A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT06208150	PHASE3	RECRUITING	A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT05461209	PHASE3	WITHDRAWN	A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
NCT04586426	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552	PHASE2	RECRUITING	A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT05695508	PHASE2	RECRUITING	GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
NCT05849610	PHASE2	ACTIVE_NOT_RECRUITING	Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
NCT05972135	PHASE2	RECRUITING	Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
NCT06066346	PHASE2	RECRUITING	A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
NCT06100237	PHASE2	RECRUITING	Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
NCT06353022	PHASE2	ACTIVE_NOT_RECRUITING	Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
NCT06461988	PHASE2	RECRUITING	Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
NCT06500884	PHASE2	RECRUITING	A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
NCT06505369	PHASE2	RECRUITING	Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
NCT06550895	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
NCT06572605	PHASE1/PHASE2	RECRUITING	External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
NCT06577025	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
NCT06827860	PHASE2	RECRUITING	Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
NCT06993675	PHASE2	RECRUITING	Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
NCT07107529	PHASE2	RECRUITING	Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
NCT03601078	PHASE2	COMPLETED	An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
NCT03399799	PHASE1	ACTIVE_NOT_RECRUITING	Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04108195	PHASE1	ACTIVE_NOT_RECRUITING	A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
NCT05050097	PHASE1	ACTIVE_NOT_RECRUITING	A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT05338775	PHASE1	ACTIVE_NOT_RECRUITING	A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
NCT06348108	PHASE1	RECRUITING	Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
NCT07032714	PHASE1	RECRUITING	Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
NCT07093554	PHASE1	RECRUITING	Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
NCT04773522	PHASE1	COMPLETED	A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
NCT06285318	Not specified	RECRUITING	A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
NCT06855121	Not specified	RECRUITING	The Norwegian Immunotherapy in Multiple Myeloma Study
NCT07499323	Not specified	NOT_YET_RECRUITING	Talquetamab in Patients With Refractory Generalized Myasthenia Gravis
NCT05503550	Not specified	NO_LONGER_AVAILABLE	Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
NCT05757973	Not specified	APPROVED_FOR_MARKETING	Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).